Skip to main content
logo
Verve Therapeutics, Inc. (VERV)
Jul 25, 2025 - VERV was delisted (reason: acquired by LLY)
11.13
0.00 (0.00%)
Inactive · Last trade price on Jul 24, 2025

Verve Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingMar '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Revenue
59.6132.3311.761.94--
Revenue Growth
271.44%174.98%505.77%---
Gross Profit
-150.82-172.02-173.19-128.15-68.2-35.37
Operating Income
-208.45-228.66-223.12-165.69-87.07-40.63
Net Income
-181.01-198.71-200.07-157.39-120.31-45.7
Earnings Per Share
-2.10-2.35-3.12-2.91-4.48-20.31
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingMar '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Cash & Investments
497.08524.28623.95554.81360.4472.11
Total Debt
68.6469.9874.9181.921.96-
Net Cash (Debt)
428.44454.3549.04472.89358.4972.11
Net Cash Growth
-19.57%-17.26%16.10%31.91%397.13%682.89%
Net Cash Per Share
4.975.368.568.7513.3432.05

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingMar '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Operating Cash Flow
-142.46-157.69-149.55-122.33-77.88-35.27
Capital Expenditures
-4.53-3.74-9.28-13.23-4.36-3.42
Free Cash Flow
-146.98-161.43-158.83-135.56-82.24-38.69
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingMar '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Operating Margin
-349.68%-707.23%-1897.64%-8536.17%--
Pretax Margin
-303.09%-613.51%-1699.21%-8105.82%--
Profit Margin
-303.63%-614.59%-1701.55%-8108.55%--
FCF Margin
-246.56%-499.28%-1350.84%-6984.23%--

Valuation
Chart
Fiscal YearCurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingAug '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
PS Ratio
16.0814.7795.35614.13--